December 3, 2018
AbbVie said on November 30 that it has filed an application seeking to expand an indication of Maviret (glecaprevir + pibrentasvir) in Japan to include pediatric patients aged 12 and over with genotypes 1-6 chronic hepatitis C. If it is...read more